Discovery and
Mechanistic Studies of Dual-Target Hits
for Carbonic Anhydrase IX and VEGFR‑2 as Potential Agents for
Solid Tumors: X‑ray, <i>In Vitro</i>, <i>In
Vivo</i>, and <i>In Silico</i> Investigations of Coumarin-Based
Thiazoles
posted on 2024-04-20, 19:04authored bySalma M. Hefny, Tarek F. El-Moselhy, Nabaweya El-Din, Simone Giovannuzzi, Thamer Bin Traiki, Mansoor-Ali Vaali-Mohammed, Ahmed M. El-Dessouki, Koki Yamaguchi, Masaharu Sugiura, Moataz A. Shaldam, Claudiu T. Supuran, Maha-Hamadien Abdulla, Wagdy M. Eldehna, Haytham O. Tawfik
A dual-targeting approach is predicted to yield better
cancer therapy
outcomes. Consequently, a series of coumarin-based thiazoles (<b>5a</b>–<b>h</b>, <b>6</b>, and <b>7a</b>–<b>e</b>) were designed and constructed as potential
carbonic anhydrase (CA) and VEGFR-2 suppressors. The inhibitory actions
of the target compounds were assessed against CA isoforms IX and VEGFR-2.
The assay results showed that coumarin-based thiazoles <b>5a</b>, <b>5d</b>, and <b>5e</b> can effectively inhibit both
targets. <b>5a</b>, <b>5d</b>, and <b>5e</b> cytotoxic
effects were tested on pancreatic, breast, and prostate cancer cells
(PANC1, MCF7, and PC3). Further mechanistic investigation disclosed
the ability of <b>5e</b> to interrupt the PANC1 cell progression
in the S stage by triggering the apoptotic cascade, as seen by increased
levels of caspases 3, 9, and BAX, alongside the Bcl-2 decline. Moreover,
the <i>in vivo</i> efficacy of compound <b>5e</b> as
an antitumor agent was evaluated. Also, molecular docking and dynamics
displayed distinctive interactions between <b>5e</b> and CA
IX and VEGFR-2 binding pockets.